99mtc psma
PeptideexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 27, 2021 (NCT04857502)
Timeline
Indications
Studied for
Mechanism of action
- Glutamate carboxypeptidase IIREDUCING AGENT
FOLH1 reducing agent
Chemistry & pharmacology
- Imaging
- 99-technetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04832958 | Phase 2 | May 15, 2021 | Vita-Salute University of Milano. Italy |
| NCT04857502 | Early Phase 1 (Phase 1) | Apr 27, 2021 | University of California, Los Angeles |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1